Clinical trials: Dryness of Mouth
Sjögren's Syndrome
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
- Trial name
- NCT07118241
- Testing
- Recombinant Human Proteoglycan 4, Vehicle Control
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Lubris Bio Pty Ltd
Sjögren's Syndrome, Sjogren's Syndrome
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against…
- Trial name
- phaethuSA (NCT04572841)
- Testing
- SAR441344
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Drug-induced Xerostomia
Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia
The purpose of this study is to evaluate the clinical efficacy, the safety and acceptability of three new oral sprays with a reference oral spray in the relief of drug-induced xerostomia associated with hyposialia, i.e.
- Trial name
- NCT02005328
- Testing
- Tested product : DC161-DP0291, Tested product : DC161-DP0292, Tested product : DC161-DP0293
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Medicament
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.
- Trial name
- NCT01706796
- Testing
- PF-06273340
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Dry Mouth, Xerostomia
Clinical Evaluation of MucoPEG™ for Xerostomia
The purpose of this study is to evaluate the effectiveness of the oral rinse comparing to MucoPEG™ and Biotene®. This is a randomized open-label crossover study with 42 patients receiving treatment.
- Trial name
- CEMPEG (NCT04986501)
- Testing
- MucoPEG, Biotene
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- SunBio, Inc.
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Dry Mouth
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence…
- Trial name
- NCT00618059
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Xerostomia
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
This will be a single center, 7-day, examiner blind, two treatment-arm, randomized, stratified (Sjogren's Syndrome status [Y/N]), parallel group study conducted in participants experiencing dry mouth symptoms.
- Trial name
- NCT02641912
- Testing
- Biotene mouthwash, Mineral Water
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adult Growth Hormone Deficiency (AGHD)
A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)
The GS3-007a Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, three-way crossover trial.
- Trial name
- NCT07259564
- Testing
- GS3-007a dry suspension, Insulin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
- Trial name
- SS (NCT04129164)
- Testing
- VIB4920
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 183 people
- Sponsor
- Amgen
Tooth Loss
Comparison of Straumann BoneCeramic vs. Allograft Bone in Extraction Sockets
The primary objective of this study is to evaluate the implant stability at the time of abutment placement on implants placed in healed extraction sockets treated with Straumann BoneCeramic (SBC) versus Freeze Dried Bone…
- Trial name
- NCT00782236
- Testing
- Bone Graft Material
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Institut Straumann AG
Oral Dryness, General Surgery
Evaluation of Safety and Efficacy of Using Lipsus Device for Oral Wetting
Following waking up from surgery performed under general anesthesia, patients are suffering from discomforting oral dryness, and moreover, they are not allowed drinking for 24 hours.
- Trial name
- NCT00945022
- Testing
- wetting lips following surgery using anesthesia
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- IMD Tech Ltd
Healthy
Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
- Trial name
- NCT00977015
- Testing
- Treatment A, Treatment B
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dry Eye Syndrome
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).
- Trial name
- NCT02092207
- Testing
- KL7016 900mg, KL7016 600mg
- Where
- 9 sites in South Korea
- Volunteers
- 147 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Healthy
Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)
To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy Japanese subjects.
- Trial name
- NCT00985348
- Testing
- Levetiracetam (Keppra)
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Coronary Artery Disease
Amlodipine Freeze-Dried Powder for Oral Solution 5 mg
The goal of this clinical study is to assess the relative bioavailability of Amlodipine for Oral Solution 5 mg of Brillian Pharma Inc.
- Trial name
- NCT05808725
- Testing
- Amlodipine Freeze-Dried Powder for Oral Solution 5 mg, Norvasc 5 mg tablets of Pfizer Labs
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Brillian Pharma Inc.